Table 6.
Medications used throughout disease course.
| Medication used during disease course | Asian (n = 134) | Black African/Caribbean (n = 69) | White Caucasian (n = 219) | P value |
|---|---|---|---|---|
| Hydroxychloroquine | 125/134 (93.3%) (89.1%, 97.5%) | 63/69 (91.3%) (84.7%, 98.0%) | 201/219 (91.8%) (88.1%, 95.4%) | 0.84 |
| Azathioprine | 50/134 (37.3%) (29.1%, 45.5%) | 24/69 (34.8%) (23.6%, 46.0%) | 101/219 (46.1%) (39.5%, 52.7%) | 0.124 |
| Mycophenolate mofetil | 85/134 (63.4%) (55.3%, 71.6%) | 45/69 (65.2%) (54.0%, 76.5%) | 112/219 (51.1%) (44.5%, 57.8%) | 0.027 |
| Cyclosporine | 3/134 (2.2%) (0.2%, 4.7%) | 4/69 (5.8%) (0.3%, 11.3%) | 4/219 (1.8%) (0.1%, 3.6%) | 0.186 |
| Methotrexate | 35/134 (26.1%) (18.7%, 33.6%) | 15/69 (21.7%) (12.0%, 31.5%) | 70/219 (32.0%) (25.8%, 38.1%) | 0.201 |
| IVIG | 17/134 (12.7%) (7.1%, 18.3%) | 4/69 (5.8%) (0.3%, 11.3%) | 14/219 (6.4%) (3.2%, 9.6%) | 0.082 |
| Rituximab | 29/134 (21.6%) (14.7%, 28.6%) | 26/69 (37.7%) (26.3%, 49.1%) | 51/219 (23.3%) (17.7%, 28.9%) | 0.030 (B vs A = 0.015) |
| Cyclophosphamide | 30/134 (22.4%) (15.3%, 29.5%) | 25/69 (36.2%) (24.9%, 47.6%) | 49/219 (22.4%) (16.9%, 27.9%) | 0.051 |
| Angiotensin receptor blocker | 15/134 (11.2%) (5.9%, 16.5%) | 13/69 (18.8%) (9.6%, 28.1%) | 26/219 (11.9%) (7.6%, 16.2%) | 0.255 |
| ACE inhibitor | 26/134 (19.4%) (12.7%, 26.1%) | 17/69 (24.6%) (14.5%, 34.8%) | 36/219 (16.4%) (11.5%, 21.3%) | 0.304 |
All medications are reported as percentages along with 95% confidence intervals. Results of post-hoc pairwise comparison tests (Fisher’s Exact test) are indicated in curved brackets under the p value, indicating where the significant differences lie using the following codes: A = Asian, B = Black African/Caribbean, C = White Caucasian.